Preoperative platelet count improves the prognostic prediction of the FIGO staging system for operable cervical cancer patients

Cervical cancer continues to be one of the most common cancers among females, being the fourth most common after breast, colorectal, and lung cancer[1]. The FIGO 2018 staging system has brought in various pathological and radiological parameters for stage classification to guide treatment related decision making and for better prognostication. OBJECTIVE: The purpose of this study is to analyse the results of stage redistribution by applying 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer patients in a tertiary care cancer centre, who were previously staged according to FIGO 2009. METHODS: Data of all cervical cancer patients who underwent various forms of treatment at our institute including surgery, radiotherapy and chemotherapy from Jan 2013 to Dec 2016 were collected from the Medical Records Department For this study, we re-staged all patients by the FIGO 2018 staging system RESULTS: The data of patients with carcinoma cervix diagnosed in the 4 years between 2013 & 2016 was tabulated according to both 2009 FIGO staging as well as 2018 FIGO staging. Significant up-staging to Stage IIIC1 & IIIC2 was noted. (Table 1& 2) CONCLUSION: The current FIGO 2018 staging system for cervical cancer appears to be useful for predicting survival in patients considering radiological and pathological variables. As per our study, majority of the cancer cervix patients fall into a single subgroup – III C1; this, in a country were already most patients present with advanced disease, will skew the data further. Stage III C1 cervical cancer is not homogenous; sub classification within stage IIIC1 may result in better prognostication.

Download Full-text

Re-classification of uterine cervical cancer cases treated with radical hysterectomy based on the 2018 FIGO staging system

Taiwanese Journal of Obstetrics and Gynecology ◽

10.1016/j.tjog.2021.09.016 ◽

2021 ◽

Vol 60 (6) ◽

pp. 1054-1058

Author(s):

Daiken Osaku ◽

Hiroaki Komatsu ◽

Masayo Okawa ◽

Yuki Iida ◽

Shinya Sato ◽

...

Keyword(s):

Cervical Cancer ◽

Radical Hysterectomy ◽

Staging System ◽

Uterine Cervical Cancer ◽

Figo Staging

Download Full-text

The prognostic role of horizontal and circumferential tumor extent in cervical cancer: Implications for the 2019 FIGO staging system

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.05.016 ◽

2020 ◽

Vol 158 (2) ◽

pp. 266-272

Author(s):

Roman E. Zyla ◽

Lilian T. Gien ◽

Danielle Vicus ◽

Ekaterina Olkhov-Mitsel ◽

Jelena Mirkovic ◽

...

Keyword(s):

Cervical Cancer ◽

Staging System ◽

Prognostic Role ◽

Figo Staging ◽

Tumor Extent

Download Full-text

The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.10.025 ◽

2020 ◽

Vol 156 (1) ◽

pp. 85-92 ◽

Cited By ~ 5

Author(s):

Kyra N. McComas ◽

Anna M. Torgeson ◽

Bryan J. Ager ◽

Christopher Hellekson ◽

Lindsay M. Burt ◽

...

Keyword(s):

Cervical Cancer ◽

Lymph Nodes ◽

Staging System ◽

Figo Staging ◽

Variable Impact ◽

Positive Lymph Nodes

Download Full-text

Is the revised 2018 FIGO staging system for cervical cancer more prognostic than the 2009 FIGO staging system for women previously staged as IB disease?

European Journal of Obstetrics & Gynecology and Reproductive Biology ◽

10.1016/j.ejogrb.2019.07.002 ◽

2019 ◽

Vol 240 ◽

pp. 209-214 ◽

Cited By ~ 3

Author(s):

Ali Ayhan ◽

Koray Aslan ◽

Ayça Nazlı Bulut ◽

Hüseyin Akilli ◽

Murat Öz ◽

...

Keyword(s):

Cervical Cancer ◽

Staging System ◽

Figo Staging

Download Full-text

Arguments for a magnetic resonance imaging–assisted FIGO staging system for cervical cancer

International Journal of Gynecological Cancer ◽

10.1136/ijgc-00009577-200507000-00001 ◽

2005 ◽

Vol 15 (4) ◽

pp. 573-582 ◽

Cited By ~ 1

Author(s):

K. Narayan

Keyword(s):

Magnetic Resonance Imaging ◽

Cervical Cancer ◽

Magnetic Resonance ◽

Cancer Biology ◽

Surgical Techniques ◽

Staging System ◽

Combined Modality Treatment ◽

Resonance Imaging ◽

Figo Staging ◽

Patient Selection Criteria

FIGO staging of cervical cancer is based on anatomic compartmental spread of cervical cancer. This was necessary in the evaluation of surgical resectability in each patient. Even if the surgical resection was not deemed satisfactory, surgical findings and subsequent accurate anatomic pathology findings could be used to prescribe tailored adjuvant therapies. Recently, the management of cervical cancer has been influenced by the evidence from several surgical-pathologic studies and phase II and III combined modality treatment trials. However, the patient selection criteria used in these clinical studies were almost always refined by modern medical imaging and surgical techniques not prescribed in the FIGO staging system. The results obtained from these studies would not correlate with those from the patient population similarly treated but selected strictly along the FIGO staging criteria. This selective, heterogenous, and arbitrary refinement of FIGO staging has certainly given insight into cervical cancer biology but in the process has rendered the current FIGO staging of this disease quite inadequate. Prior knowledge of these factors through modern imaging in these patients could be used in staging and selecting the optimum treatment modality while minimizing the treatment-related morbidity. A magnetic resonance imaging-assisted FIGO staging system for cervical cancer as proposed here could be used for selecting patients appropriately for a given treatment package

Download Full-text

PROGNOSTIC SIGNIFICANCE OF THE CENTRAL TUMOR SIZE ( CTS) IN STAGES IIB AND IIIB BULKY CERVICAL CANCER (CC): proposing a new FIGO staging system

10.26226/morressier.5d2ee8e91e09a6f49485aab8 ◽

2019 ◽

Author(s):

Alejandro Soderini ◽

Alejandro Aragona

Keyword(s):

Cervical Cancer ◽

Tumor Size ◽

Prognostic Significance ◽

Staging System ◽

Figo Staging

Download Full-text

Prognostic value of preoperative peripheral blood mean platelet volume/platelet count ratio (MPV/PC) in patients with resectable cervical cancer

BMC Cancer ◽

10.1186/s12885-021-09016-8 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Qicheng Deng ◽

Qifang Long ◽

Yanan Liu ◽

Zhujuan Yang ◽

Yibei Du ◽

...

Keyword(s):

Cervical Cancer ◽

Platelet Count ◽

Cancer Patients ◽

Prognostic Value ◽

Validation Cohort ◽

Radical Surgery ◽

Survival Rates ◽

Platelet Volume ◽

Lymphocyte Ratio ◽

Figo Classification

Abstract Background The mean platelet volume/platelet count ratio (MPV/PC) ratio based on the preoperative peripheral MPV and PCcan be used to predict the prognosis of multiple malignant tumors. Objective To evaluate the prognostic value of MPV/PC in cervical cancer patients. Methods This study enrolled 408 patients who had undergone radical surgery for cervical cancer and evaluated the correlation of MPV/PC with patient prognosis in the primary cohort and validation cohort. Additionally, independent prognostic factors were incorporated to construct the prognostic nomogram, and the area under the receiver operating characteristic (ROC) curve (AUC) value was calculated to analyze the prognostic predictive ability of the nomogram. Results In the primary cohort, Kaplan–Meier survival analysis indicated that the overall survival (OS) for patients with MPV/PC ≤ 0.41 was significantly lower than that in patients with MPV/PC > 0.41. MPV/PC was an independent prognostic factor for resectable cervical cancer patients. Compared with neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) or monocyte/lymphocyte ratio (MLR), the AUC values of MPV/PC in predicting the 3- and 5-year survival rates for cervical cancer patients were greater. Similar results were verified in the validation cohort. Subsequently, the nomogram constructed based on MPV/PC, International Federation of Gynecology and Obstetrics (FIGO) classification and lymphovascular invasion performed well to accurately predict the prognosis of cervical cancer patients. The 3- and 5-year survival rates predicted by the nomogram were highly consistent with the real observations. Similar results were also displayed in the validation cohort. Conclusions MPV/PC may be used as a novel independent prognostic factor for patients with resectable cervical cancer. Compared with the FIGO classification system, the nomogram integrating MPV/PC maybe reliably predict the survival of cervical cancer patients after radical surgery.

Download Full-text

Validation of The 2018 FIGO Staging System for Predicting The Prognosis of Patients With Stage IIIC Cervical Cancer

10.21203/rs.3.rs-708694/v1 ◽

2021 ◽

Author(s):

Xingtao Long ◽

Qi Zhou ◽

Dongling Zou ◽

Dong Wang ◽

Jingshu Liu ◽

...

Keyword(s):

Cervical Cancer ◽

Multivariable Analysis ◽

Staging System ◽

Risk Of Death ◽

T Stage ◽

Figo Staging ◽

Gynecology And Obstetrics ◽

Risk Of Mortality ◽

Increased Risk ◽

Standardized Treatment

Abstract Purpose We aimed to validate the prognostic performance of the 2018 International Federation of Gynecology and Obstetrics(FIGO) IIIC staging system for patients with cervical cancer. Methods We conducted a retrospective analysis of patients with stage III cervical cancer according to the 2018 FIGO staging system who received standardized treatment from January 2011 to December 2014. Results Multivariable analysis revealed that stage IIIC1 was not significantly associated with increased risk of death compared with stages IIIA (hazard ratio [HR] = 1.432; 95% confidence interval [CI]: 0.867 to 2.366; P = 0.161) and IIIB (HR = 1.261; 95% CI: 0.871 to 1.827; P = 0.219). Stage IIIC2 was an independent indicator of increased risk of mortality compared with stages IIIA (HR = 2.958; 95% CI :1.757 to 4.983; P < 0.001) and IIIB (HR = 2.606; 95% CI: 1.752 to 3.877; P < 0.001). We stratified patients with stage IIIC1 according to T stage and compared survival outcomes. Stage IIIC1 (T1) was associated with longer 5-year overall survival (OS) compared with stages IIIA (P = 0.004) or IIIB (P < 0.001). An optimal cut-off value (= 2) was established for predicting the prognosis of stage IIIC1p(T1/T2a), which was associated with the number of pelvic lymph nodes metastases (PLNMs). Patients with stage IIIC1pN1-2 experienced longer 5-year OS compared those with stages IIIA (P = 0.01) or IIIB (P < 0.001). Conclusion Patients with stage IIIC1 cervical cancer exhibited heterogeneous clinical characteristics reflecting their variable prognoses, depending on T-stage and the extent of PLNMs

Download Full-text